Cargando…
Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
INTRODUCTION: The aim of the study was to assess the clinical efficacy, safety, and disease-modification effects of tramiprosate (homotaurine, ALZHEMED(TM)) in mild-to-moderate Alzheimer’s disease (AD). MATERIAL AND METHODS: Double-blind, placebo-controlled, randomized trial in 67 clinical centres a...
Autores principales: | Aisen, Paul S., Gauthier, Serge, Ferris, Steven H., Saumier, Daniel, Haine, Denis, Garceau, Denis, Duong, Anh, Suhy, Joyce, Oh, Joonmi, Lau, Wan C., Sampalis, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258678/ https://www.ncbi.nlm.nih.gov/pubmed/22291741 http://dx.doi.org/10.5114/aoms.2011.20612 |
Ejemplares similares
-
A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders
por: Manzano, Sagrario, et al.
Publicado: (2020) -
Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016) -
Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau
por: Santa-Maria, Ismael, et al.
Publicado: (2007) -
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
por: Hey, John A., et al.
Publicado: (2017) -
Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
por: Schwarz, Adam J., et al.
Publicado: (2019)